On January 8, 2026, Piper Sandler set a price target of $16 for Ardelyx, indicating a potential upside of approximately 71.43%. Wall Street analysts have established an average target that implies a 92.1% gain, reflecting broad optimism about ARDX’s long-term prospects. Short-term estimates among the research community range from $8 to $16, with a mean of $11.70, suggesting potential increases between 31.4% and 162.7% from current levels and underscoring variability in consensus projections.

Over the past four weeks, ARDX has climbed 3.6%, with the most recent close at $6.09. During today’s session it traded between $6.12 and a one-year high of $7.10, while its 52-week low stands at $3.21. The company’s market capitalization is roughly $1.68 billion, and trading volume reached 15.38 million shares, signaling elevated investor interest and strengthening the case for follow-through on positive analyst revisions.

Ardelyx reported preliminary full-year 2025 product revenue of approximately $378 million, up 18% year-over-year. Its lead product, IBSRELA, generated $274 million in 2025—73% growth over 2024—with $87 million in the fourth quarter alone. XPHOZAH contributed $104 million for the year, including $28 million in Q4. As of December 31, 2025, the company held $265 million in cash, cash equivalents and investments. Ardelyx forecasts 2026 IBSRELA revenue of $410–430 million (at least 50% growth) and anticipates $110–120 million for XPHOZAH. Long-term guidance projects IBSRELA reaching $1 billion in annual sales by 2029. The company has commenced a Phase 3 trial for IBSRELA in chronic idiopathic constipation, received a Notice of Allowance extending product patents to December 2041, and advanced RDX10531 as a next-generation NHE3 inhibitor.